Soluble urokinase plasminogen activator receptor (suPAR) is a molecule, or biomarker, that circulates in the blood and is easily tested. People with high suPAR levels have a much higher likelihood of developing kidney disease. Most importantly, it is possible that suPAR itself may be a cause of kidney disease. We have identified genetic variants that are predict suPAR levels. The purpose of this study using data from the UK Biobank participants is to determine whether these variants themselves are associated with kidney disease, using an analytical technique called Mendelian randomization. Evidence of an association between genetic variants related to suPAR and kidney disease will provide supportive evidence for suPAR as a cause of kidney disease. Several anti-suPAR therapies are in development which may change the landscape of kidney disease treatment. This study will provide supportive evidence justifying the trial of these new therapies in the treatment and prevention of kidney disease.